DE3486293T4 - Impfstoff-Zubereitung. - Google Patents
Impfstoff-Zubereitung.Info
- Publication number
- DE3486293T4 DE3486293T4 DE3486293T DE3486293T DE3486293T4 DE 3486293 T4 DE3486293 T4 DE 3486293T4 DE 3486293 T DE3486293 T DE 3486293T DE 3486293 T DE3486293 T DE 3486293T DE 3486293 T4 DE3486293 T4 DE 3486293T4
- Authority
- DE
- Germany
- Prior art keywords
- ccv
- cells
- virus
- dogs
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 128
- 238000002360 preparation method Methods 0.000 title description 5
- 241000711506 Canine coronavirus Species 0.000 claims abstract description 246
- 241000282472 Canis lupus familiaris Species 0.000 claims abstract description 207
- 241000700605 Viruses Species 0.000 claims abstract description 163
- 230000036039 immunity Effects 0.000 claims abstract description 28
- 210000000936 intestine Anatomy 0.000 claims abstract description 16
- 208000015181 infectious disease Diseases 0.000 claims description 71
- 238000000034 method Methods 0.000 claims description 53
- 239000002671 adjuvant Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 30
- 102000036639 antigens Human genes 0.000 claims description 30
- 108091007433 antigens Proteins 0.000 claims description 30
- 238000011081 inoculation Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- 230000009467 reduction Effects 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 17
- 230000002458 infectious effect Effects 0.000 claims description 16
- 241000711573 Coronaviridae Species 0.000 claims description 14
- 230000009885 systemic effect Effects 0.000 claims description 14
- 206010022678 Intestinal infections Diseases 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 12
- 239000002356 single layer Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000000415 inactivating effect Effects 0.000 claims description 10
- 238000003306 harvesting Methods 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000010410 layer Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 abstract description 15
- 241000282324 Felis Species 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 88
- 238000002255 vaccination Methods 0.000 description 79
- 210000004027 cell Anatomy 0.000 description 44
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 210000001035 gastrointestinal tract Anatomy 0.000 description 37
- 210000004698 lymphocyte Anatomy 0.000 description 37
- 239000012530 fluid Substances 0.000 description 35
- 210000000265 leukocyte Anatomy 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 29
- 230000000968 intestinal effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 230000007423 decrease Effects 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 201000010099 disease Diseases 0.000 description 24
- 238000007790 scraping Methods 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 18
- 230000029812 viral genome replication Effects 0.000 description 18
- 230000007613 environmental effect Effects 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 241000701931 Canine parvovirus Species 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 13
- 241000282465 Canis Species 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000004232 Enteritis Diseases 0.000 description 10
- 210000002418 meninge Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 8
- 239000013066 combination product Substances 0.000 description 8
- 229940127555 combination product Drugs 0.000 description 8
- 238000007918 intramuscular administration Methods 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 230000000405 serological effect Effects 0.000 description 8
- 206010025327 Lymphopenia Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 231100001023 lymphopenia Toxicity 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241000712083 Canine morbillivirus Species 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 101100172132 Mus musculus Eif3a gene Proteins 0.000 description 6
- 206010039101 Rhinorrhoea Diseases 0.000 description 6
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004534 cecum Anatomy 0.000 description 6
- 210000001198 duodenum Anatomy 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 208000010753 nasal discharge Diseases 0.000 description 6
- 229960000380 propiolactone Drugs 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000003437 trachea Anatomy 0.000 description 6
- 230000009385 viral infection Effects 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 208000005577 Gastroenteritis Diseases 0.000 description 5
- 208000036142 Viral infection Diseases 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000013553 cell monolayer Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000004299 exfoliation Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000001630 jejunum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 4
- 241000701157 Canine mastadenovirus A Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 230000005875 antibody response Effects 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- YYXLGGIKSIZHSF-UHFFFAOYSA-N ethene;furan-2,5-dione Chemical compound C=C.O=C1OC(=O)C=C1 YYXLGGIKSIZHSF-UHFFFAOYSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 241000125945 Protoparvovirus Species 0.000 description 3
- 241000711484 Transmissible gastroenteritis virus Species 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- WJAXXWSZNSFVNG-UHFFFAOYSA-N 2-bromoethanamine;hydron;bromide Chemical compound [Br-].[NH3+]CCBr WJAXXWSZNSFVNG-UHFFFAOYSA-N 0.000 description 2
- -1 7715 Chemical compound 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001353878 Canine parainfluenza virus Species 0.000 description 2
- 241001493036 Canine rotavirus Species 0.000 description 2
- 101150047856 Cav2 gene Proteins 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 206010015915 eye discharge Diseases 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- SXXHYAMKYMNIHI-UHFFFAOYSA-N fluoroimino(sulfanylidene)methane Chemical compound FN=C=S SXXHYAMKYMNIHI-UHFFFAOYSA-N 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 229960003127 rabies vaccine Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 241001279357 Canine calicivirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100038909 Caveolin-2 Human genes 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241001550390 Leptospira interrogans serovar Canicola Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- CJIZDSMQDFSIAU-UHFFFAOYSA-J [OH-].[Al+3].P(=O)([O-])([O-])[O-].[Al+3] Chemical compound [OH-].[Al+3].P(=O)([O-])([O-])[O-].[Al+3] CJIZDSMQDFSIAU-UHFFFAOYSA-J 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OXJUJQDEISSCTB-UHFFFAOYSA-N but-3-en-2-imine Chemical compound CC(=N)C=C OXJUJQDEISSCTB-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940001442 combination vaccine Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
- C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Claims (18)
1. Verfahren zur Herstellung einer Veterinärvakzin-
Zusammensetzung, enthaltend eine ausreichende Menge von
Hundecoronavirus(CCV)-Antigen zur Erzeugung einer Immunreaktion
beim Hund, einen pharmazeutisch akzeptablen
veterinärmedizinischen Träger und mindestens ein Adjuvans,
welches Verfahren die Gewinnung des CCV-Antigens durch
Inokulieren von Gewebezellkulturen von Säugern mit CCV, die
Kultivierung der Zellen in eine dichte konfluente
Einzelzellschicht vor dem Inokulationsschritt oder innerhalb
von 24 Stunden ab dem Inokulationsschritt, das Ernten der
Zellen innerhalb von 96 Stunden ab der Inokulation und die
Inaktivierung sämtlicher Viren in den geernteten Zellen, wobei
der Präinaktivierungsvirustiter in dem Verfahren mindestens
etwa 1000 Virusteilchen pro ml, gemessen durch die FAID&sub5;&sub0;-
Methode, beträgt, und das Formulieren des erhaltenen CCV-
Antigens mit dem Träger und dem Adjuvans umfaßt.
2. Verfahren nach Anspruch 1, worin der
Präinaktivierungstiter etwa 4,0 log Virusteilchen pro ml
beträgt.
3. Verfahren nach Anspruch 1 oder 2, worin etwa zur
Inokulationszeit die Zellen in einer Menge vorhanden sind, die
zur Bildung einer Einzelzellschicht mit mindestens 100 000
Zellen pro cm² ausreicht.
4. Verfahren nach einem der Ansprüche 1 bis 3, worin die
Zellen in einer Menge vorhanden sind, die zur Bildung einer
Einzelzellschicht mit etwa 150 000 Zellen pro cm² ausreicht.
5. Verfahren nach einem der AnsPrüche 1 bis 4, worin die
Zellen in einem Verhältnis von CCV-Viren, gemessen durch die
FAID&sub5;&sub0;-Methode, zu Zellen von etwa 1:1 bis etwa 1:500 mit CCV
inokuliert werden.
6. Verfahren nach einem der Ansprüche 1 bis 4, worin die
Zellen in einem Verhältnis von CCV-Viren, gemessen durch die
FAID&sub5;&sub0;-Methode, zu Zellen von etwa 1:100 mit CCV inokuliert
werden.
7. Verfahren nach einem der Ansprüche 1 bis 6, worin das
inokulierte Virus vor der Kultivierung weniger als 300 Minuten
in einem Kulturmedium auf den Zellen absorbiert wird.
8. Verfahren zur Herstellung einer Veterinärvakzin-
Zusammensetzung, enthaltend eine ausreichende Menge von
Hundecoronavirus (CCV) -Antigen zur Erzeugung einer Immunreaktion
beim Hund, einen pharmazeutisch akzeptablen
veterinärmedizinischen Träger und mindestens ein Adjuvans,
welches Verfahren die Gewinnung des CCV-Antigens durch
Inokulieren von Gewebezellkulturen von Säugern mit CCV, das
Ernten der Zellen, nachdem Virustiter von mindestens 2 000
Teilchen pro ml, gemessen durch die FAID&sub5;&sub0;-Methode, erreicht
worden sind, das Sammeln des von Lebendvirus freien CCV-
Antigens und die Formulierung des erhaltenen CCV-Antigens mit
dem Träger und dem Adjuvans umfaßt.
9. Verfahren nach Anspruch 8, worin die Zellen in einer Menge
vorhanden sind, die zur Bildung einer Einzelschicht mit
mindestens etwa 100 000 Zellen pro cm² ausreicht, und die
Zellen in einem Verhältnis von CCV-Viren, gemessen durch die
FAID&sub5;&sub0;-Methode, zu Zellen von etwa 1:1 bis etwa 1:500 mit CCV
inokuliert werden.
10. Verfahren nach Anspruch 8 oder 9, worin die Zellen
geerntet werden, nachdem Virustiter von mindestens 4 log
Virusteilchen, gemessen durch die FAID&sub5;&sub0;-Methode, erhalten sind.
11. Verfahren nach einem der Ansprüche 8 bis 10, worin die
Zellen innerhalb von 96 Stunden oder weniger nach der
Inokulierung geerntet werden.
12. Verfahren zur Herstellung einer Veterinärvakzin-
Zusammensetzung, enthaltend einen pharmazeutisch akzeptablen
veterinärmedizinischen Träger, zumindest ein Adjuvans zur
Förderung der Immunreaktion und eine ausreichende Menge
Coronavirusantigen zur Erzeugung einer protektiven
Immunreaktion bei Hunden, die bei einer späteren virulenten
Hundecoronavirus (CCV)-Exposition eine Reduktion der
Darminfektion von mindestens etwa 80 % bewirkt, welches
Verfahren die Gewinnung des CCV-Antigens durch Inokulieren von
Gewebezellkulturen von Säugern mit einem Impfvirus zur
Erzeugung von CCV-Antigen, die Kultivierung der Zellen zu einer
dichten konfluenten Einzelzellschicht vor dem
Inokulationsschritt oder innerhalb von 24 Stunden ab dem
Inokulationsschritt in einer Menge, die zur Bildung einer
Einzelzellschicht mit mindestens 100 000 Zelle pro cm²
ausreicht, gegebenenfalls das Absorbieren des Impfvirus an den
Zellen über einen Zeitraum von bis zu 300 Minuten, das Ernten
der Zellen, nachdem Virustiter von mindestens 4 log Teilchen
pro ml, gemessen durch die FAID&sub5;&sub0;-Methode, erreicht worden sind,
das Sammeln des von Lebendvirus freien Antigens und das
Formulieren des erhaltenen CCV-Antigens mit dem Träger und dem
Adjuvans umfaßt.
13. Verfahren nach Anspruch 12, worin die Zellen zum Zeitpunkt
der Inokulation in einer Menge vorhanden sind, die zur Bildung
einer Einzelzellschicht mit mindestens 100 000 Zellen pro cm²
ausreicht.
14. Verfahren nach einem der Ansprüche 12 oder 13, worin die
Zellen mit ausreichendem Virus inokuliert werden, um ein
minimales Infektionsmultiplizitätsverhältnis von etwa 1:500 zu
erreichen.
15. Verfahren nach einem der Ansprüche 12 bis 14, worin das
Impfvirus etwa 60 Minuten lang an den Zellen absorbiert wird.
16. Verfahren zur Herstellung eines Hundecoronavirus(CCV)-
Vakzins, umfassend die folgenden Schritte:
a) Inokulieren von Gewebekulturzellen von Säugern mit einer
CCV-Menge (gemessen durch die FAID&sub5;&sub0;-Methode), die zur Erzielung
eines minimalen Infektionsmultiplizitätsverhältnisses (MOI) von
etwa 1:500 ausreicht;
b) Kultivieren der Zellen zu einer dichten konfluenten
Einzelzellschicht vor dem Inokulationsschritt oder innerhalb
von etwa 12 bis 48 Stunden ab dem lnokulationsschritt, wobei
die Zellen zur Zeit der Inokulation in einer Menge von
mindestens etwa 100 000 Zellen pro cm² vorhanden sind;
c) Ernten der Zellen innerhalb von 96 Stunden ab der
Inokulation zur Gewinnung des CCV-Antigens;
d) lnaktivieren des mit den Zellen geernteten CCV-Virus zur
Gewinnung einer inaktivierten CCV-Antigenzusammensetzung;
e) Zusetzen mindestens eines Adjuvans zur inaktivierten CCV-
Antigenzusammensetzung; und
f) Herstellen des CCV-Vakzins, enthaltend die inaktivierte
CCV-Antigenzusammensetzung, einen pharmazeutisch akzeptablen
Träger und zumindest ein Adjuvans.
17. Veterinärvakzinzusammensetzung, umfassend ein von
Lebendvirus freies Coronavirusantigen in einer parenteral
wirksamen Menge zur Erzeugung systemischer Immunität und
lokaler Immunität im Darm von Hunden gegen eine Infektion mit
virulentem Hundecoronavirus, einen pharmazeutisch akzeptablen
veterinärmedizinischen Träger und zumindest ein Adjuvans.
18. Veterinärvakzinzusammensetzung, umfassend ein von
Lebendvirus freies Coronavirusantigen in einer zur Erzeugung
von alpha-Immunglobulin(IgA)-Antikörpern und zur Induktion von
lokaler Immunität im Darm gegen infektiösen Hundecoronavirus
ausreichenden Menge, einen pharmazeutisch akzeptablen
veterinärmedizinischen Träger und zumindest ein Adjuvans.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/504,434 US4567043A (en) | 1983-06-15 | 1983-06-15 | Canine corona virus vaccine |
US06/618,638 US4567042A (en) | 1983-06-15 | 1984-06-07 | Inactivated canine coronavirus vaccine |
EP19890201017 EP0329264B1 (de) | 1983-06-15 | 1984-06-14 | Tierärztliche Impfstoffe |
PCT/US1984/000904 WO1985000014A1 (en) | 1983-06-15 | 1984-06-14 | Canine coronavirus vaccine |
Publications (4)
Publication Number | Publication Date |
---|---|
DE3486293D1 DE3486293D1 (de) | 1994-04-28 |
DE3486293T2 DE3486293T2 (de) | 1994-06-30 |
DE3486293T4 true DE3486293T4 (de) | 1995-06-14 |
DE3486293T3 DE3486293T3 (de) | 2002-11-21 |
Family
ID=27054825
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3486495T Expired - Lifetime DE3486495D1 (de) | 1983-06-15 | 1984-06-14 | Hundecoronavirus |
DE8484902632T Expired - Lifetime DE3481582D1 (de) | 1983-06-15 | 1984-06-14 | Impfstoff gegen hundecoronavirus. |
DE3486292T Expired - Lifetime DE3486292T2 (de) | 1983-06-15 | 1984-06-14 | Tierärztliche Impfstoffe. |
DE3486293T Expired - Lifetime DE3486293T3 (de) | 1983-06-15 | 1984-06-14 | Impfstoff-Zubereitung. |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE3486495T Expired - Lifetime DE3486495D1 (de) | 1983-06-15 | 1984-06-14 | Hundecoronavirus |
DE8484902632T Expired - Lifetime DE3481582D1 (de) | 1983-06-15 | 1984-06-14 | Impfstoff gegen hundecoronavirus. |
DE3486292T Expired - Lifetime DE3486292T2 (de) | 1983-06-15 | 1984-06-14 | Tierärztliche Impfstoffe. |
Country Status (7)
Country | Link |
---|---|
US (1) | US4567042A (de) |
EP (4) | EP0329264B1 (de) |
AT (4) | ATE280217T1 (de) |
DE (4) | DE3486495D1 (de) |
ES (1) | ES8604422A1 (de) |
NL (1) | NL940017I2 (de) |
WO (1) | WO1985000014A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4990367A (en) * | 1987-03-09 | 1991-02-05 | Diamond Scientific Company | Canine distemper virus vaccine |
EP0283085B1 (de) * | 1987-03-17 | 1992-11-11 | Akzo N.V. | Adjuvanzienmischung |
US5565209A (en) * | 1987-03-17 | 1996-10-15 | Akzo Nobel N.V. | Adjuvant mixture |
US4904468A (en) * | 1987-06-08 | 1990-02-27 | Norden Laboratories, Inc. | Canine coronavirus vaccine |
US5911999A (en) * | 1987-09-28 | 1999-06-15 | Pfizer, Inc. | Vaccine based on TGEV for protection of dogs against canine coronavirus |
ZA903142B (en) * | 1989-05-03 | 1991-02-27 | Akzo Nv | Canine corona virus vaccine |
US5672350A (en) * | 1989-08-22 | 1997-09-30 | Veterinary Infectious Disease Organization | Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines |
US6004563A (en) * | 1990-11-07 | 1999-12-21 | American Home Products Corporation | Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same |
US6057436A (en) * | 1990-11-14 | 2000-05-02 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
US6372224B1 (en) | 1990-11-14 | 2002-04-16 | Pfizer Inc. | Canine coronavirus S gene and uses therefor |
DK0510773T3 (da) * | 1991-04-25 | 2004-04-19 | Akzo Nobel Nv | Canine coronavirus subunit-vaccine |
US5750112A (en) * | 1993-02-26 | 1998-05-12 | Solvay Animal Health, Inc. | Canine coronavirus vaccine from feline enteric coronavirus |
US20040053208A1 (en) * | 1995-08-29 | 2004-03-18 | V. I. TECHNOLOGIES, Inc. | Methods to selectively inactivate parasites in biological compositions |
US20040048235A1 (en) * | 1995-08-29 | 2004-03-11 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
GB9622159D0 (en) * | 1996-10-24 | 1996-12-18 | Solvay Sociutu Anonyme | Polyanionic polymers as adjuvants for mucosal immunization |
US6093564A (en) * | 1997-10-03 | 2000-07-25 | V.I. Technologies, Inc. | Methods and compositions for the selective modification of nucleic acids |
US6369048B1 (en) | 1998-01-12 | 2002-04-09 | V.I. Technologies, Inc. | Methods and compositions for inactivating viruses |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
US6617100B2 (en) | 1998-09-25 | 2003-09-09 | V.I. Technologies, Inc. | Solid phase quenching systems |
US6150109A (en) | 1999-01-25 | 2000-11-21 | V. I. TECHNOLOGIES, Inc. | Lipophilic quenching of viral inactivating agents |
US20020131958A1 (en) * | 2001-01-22 | 2002-09-19 | John Chapman | Method for purifying a biological composition |
US20030129161A1 (en) * | 2001-09-17 | 2003-07-10 | Hsien-Jue Chu | Interleukin-12 as a veterinary vaccine adjuvant |
EP1575613A1 (de) * | 2002-12-19 | 2005-09-21 | Akzo Nobel | Trivalenter impfstoff mit maternalem antikörpertransfer über die muttermilch |
JP2006515024A (ja) * | 2003-01-29 | 2006-05-18 | ファイザー・プロダクツ・インク | Bordetellabronchisepticaに対するイヌワクチン |
US20050089533A1 (en) * | 2003-01-29 | 2005-04-28 | Joseph Frantz | Canine vaccines against Bordetella bronchiseptica |
GB0315323D0 (en) * | 2003-07-01 | 2003-08-06 | Royal Veterinary College | Vaccine composition |
US9023366B2 (en) | 2003-07-01 | 2015-05-05 | The Royal Veterinary College | Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD) |
US20060257429A1 (en) * | 2003-10-23 | 2006-11-16 | Dreier Kimberly J | Vaccine for periodontal disease |
CA2604488A1 (en) * | 2005-04-07 | 2006-10-12 | Pharmacia & Upjohn Company Llc | Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines |
DE602005025649D1 (de) * | 2005-10-26 | 2011-02-10 | Canio Buonavoglia | Pantropisches Hundecoronavirus |
US7682619B2 (en) * | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
KR101013226B1 (ko) * | 2008-05-14 | 2011-02-10 | 녹십자수의약품(주) | 개 바이러스성 설사병 예방용 백신 |
US20110110980A1 (en) * | 2009-09-02 | 2011-05-12 | Wyeth Llc | Heterlogous prime-boost immunization regimen |
UY34745A (es) | 2012-04-18 | 2013-11-29 | Zoetis Llc | Vacunas y procedimientos para tratar la enfermedad de lyme en perros |
US20140170180A1 (en) | 2012-12-17 | 2014-06-19 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5a, methods of use and vaccine |
US20140234354A1 (en) | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
WO2014150822A2 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use |
WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
CN113924111A (zh) | 2019-01-04 | 2022-01-11 | 勃林格殷格翰动物保健美国公司 | 减毒的支气管败血性博德特菌菌株、包含该减毒的菌株的口服疫苗及其制备和使用方法 |
CN109765384B (zh) * | 2019-01-29 | 2022-11-18 | 北京勤邦生物技术有限公司 | 一种犬冠状病毒抗体荧光检测试纸条及其制备方法和应用 |
CN112402599B (zh) * | 2019-08-23 | 2023-06-27 | 中国农业科学院特产研究所 | 一种犬用犬瘟热、细小病毒病二联灭活疫苗及其制备方法 |
WO2022149342A1 (ja) * | 2021-01-06 | 2022-07-14 | パナソニックホールディングス株式会社 | ***物判定方法、***物判定装置、及び***物判定プログラム |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3143474A (en) * | 1962-07-30 | 1964-08-04 | Sterling Drug Inc | Preparation of duck-embryo modified infectious canine hepatitis virus vaccine |
US3704203A (en) † | 1967-08-24 | 1972-11-28 | Diamond Lab Inc | Transmissible gastroenteritis vaccines and methods of producing the same |
US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
US3959251A (en) * | 1970-06-25 | 1976-05-25 | Exploaterings Aktiebolaget T.B.F. | Stabilized agar product and method for its stabilization |
-
1984
- 1984-06-07 US US06/618,638 patent/US4567042A/en not_active Expired - Lifetime
- 1984-06-14 EP EP19890201017 patent/EP0329264B1/de not_active Expired - Lifetime
- 1984-06-14 DE DE3486495T patent/DE3486495D1/de not_active Expired - Lifetime
- 1984-06-14 EP EP19890201996 patent/EP0345911B1/de not_active Expired - Lifetime
- 1984-06-14 AT AT89201996T patent/ATE280217T1/de not_active IP Right Cessation
- 1984-06-14 EP EP89202001A patent/EP0344872B2/de not_active Expired - Lifetime
- 1984-06-14 EP EP84902632A patent/EP0145783B2/de not_active Expired - Lifetime
- 1984-06-14 DE DE8484902632T patent/DE3481582D1/de not_active Expired - Lifetime
- 1984-06-14 WO PCT/US1984/000904 patent/WO1985000014A1/en active IP Right Grant
- 1984-06-14 DE DE3486292T patent/DE3486292T2/de not_active Expired - Lifetime
- 1984-06-14 DE DE3486293T patent/DE3486293T3/de not_active Expired - Lifetime
- 1984-06-14 AT AT84902632T patent/ATE50913T1/de not_active IP Right Cessation
- 1984-12-14 ES ES538588A patent/ES8604422A1/es not_active Expired
-
1989
- 1989-04-20 AT AT89201017T patent/ATE103181T1/de not_active IP Right Cessation
- 1989-07-31 AT AT89202001T patent/ATE103180T1/de not_active IP Right Cessation
-
1994
- 1994-08-18 NL NL940017C patent/NL940017I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
DE3486292D1 (de) | 1994-04-28 |
DE3486293T3 (de) | 2002-11-21 |
WO1985000014A1 (en) | 1985-01-03 |
EP0345911B1 (de) | 2004-10-20 |
ES538588A0 (es) | 1986-02-01 |
EP0145783B2 (de) | 2004-01-02 |
ATE280217T1 (de) | 2004-11-15 |
DE3486293T2 (de) | 1994-06-30 |
EP0145783A4 (de) | 1985-10-14 |
DE3481582D1 (de) | 1990-04-19 |
DE3486292T2 (de) | 1994-06-30 |
EP0145783A1 (de) | 1985-06-26 |
EP0344872B2 (de) | 2002-04-24 |
EP0329264B1 (de) | 1994-03-23 |
ES8604422A1 (es) | 1986-02-01 |
ATE103180T1 (de) | 1994-04-15 |
ATE103181T1 (de) | 1994-04-15 |
NL940017I1 (nl) | 1994-10-17 |
EP0344872A1 (de) | 1989-12-06 |
EP0145783B1 (de) | 1990-03-14 |
DE3486293D1 (de) | 1994-04-28 |
EP0345911A1 (de) | 1989-12-13 |
US4567042A (en) | 1986-01-28 |
EP0329264A3 (en) | 1989-12-13 |
NL940017I2 (nl) | 2001-02-01 |
EP0344872B1 (de) | 1994-03-23 |
DE3486495D1 (de) | 2004-11-25 |
EP0329264A2 (de) | 1989-08-23 |
ATE50913T1 (de) | 1990-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3486293T4 (de) | Impfstoff-Zubereitung. | |
DE3852918T2 (de) | TGEV-Virus vom Schwein als Impfstoff für Hunde. | |
Timms et al. | Cell‐mediated immune response of chickens to Newcastle disease vaccines | |
DE19612967A1 (de) | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren | |
DE3882599T2 (de) | Hundecoronavirus-Impfstoff. | |
Patnayak et al. | Experimental and field evaluation of a live vaccine against avian pneumovirus | |
CH617588A5 (de) | ||
US5047238A (en) | Adjuvants for vaccines | |
DE2713371A1 (de) | Impfstoff gegen die rhinotracheitis der katze und verfahren zu seiner herstellung | |
CH504532A (de) | Verfahren zur Züchtung pathogener Viren, Zellstamm zur Ausführung des Verfahrens und Anwendung des Verfahrens | |
CA1184115A (en) | Infectious bronchitis vaccines for poultry and process for the preparation of such vaccines | |
DE69333730T2 (de) | Impfstoff, der acemannan als adjuvans enthält | |
DE2323847C3 (de) | Lebendimpfstoff zur Immunisierung von Rindern gegen die Parainfluenza-3-Virus-Infektion | |
DE3853736T2 (de) | Staupevirus-Impfstoff. | |
DE69535059T2 (de) | Borrelia burgdorferi bacterin | |
CA1183452A (en) | Rabies vaccine | |
McFerran et al. | Isolation and characterisation of sheep adenoviruses | |
Vanselow et al. | Field trials of ephemeral fever vaccines | |
DE69014974T2 (de) | Impfstoff gegen Hundecoronavirus. | |
DE3888775T2 (de) | Impfstoff für den Schutz von Katzen gegen infektiöse Katzenperitonitis. | |
Potgieter et al. | Isolation of a herpesvirus from an American kestrel with inclusion body disease | |
Haddad et al. | Assay of oral vaccination of dogs against rabies in Tunisia with the vaccinal strain SADBern | |
Chang et al. | Vaccination Against Marek's Disease and Infectious Bursal Disease: 1. Development of a Bivalent Live Vaccine by Co-Cultivating Turkey Herpesvirus and Infectious Bursal Disease Vaccine Viruses in Chicken Embryo Fibroblast Monolayers | |
RU2301079C2 (ru) | Вакцина против коронавирусной инфекции крупного рогатого скота сорбированная инактивированная | |
JPS6244528B2 (de) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8366 | Restricted maintained after opposition proceedings | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: WYETH (N.D.GES.D. STAATES DELAWARE), MADISON, N.J. |